Novel insights into PORCN mutations, associated phenotypes and pathophysiological aspects.

Connective tissue disorder ER-stress Fibroblast proteomics Focal dermal hypoplasia Goltz syndrome Lamin a/c Protein-serine O-palmitoleoyltransferase porcupine

Journal

Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602

Informations de publication

Date de publication:
31 01 2022
Historique:
received: 29 12 2020
accepted: 30 09 2021
entrez: 1 2 2022
pubmed: 2 2 2022
medline: 12 3 2022
Statut: epublish

Résumé

Goltz syndrome (GS) is a X-linked disorder defined by defects of mesodermal- and ectodermal-derived structures and caused by PORCN mutations. Features include striated skin-pigmentation, ocular and skeletal malformations and supernumerary or hypoplastic nipples. Generally, GS is associated with in utero lethality in males and most of the reported male patients show mosaicism (only three non-mosaic surviving males have been described so far). Also, precise descriptions of neurological deficits in GS are rare and less severe phenotypes might not only be caused by mosaicism but also by less pathogenic mutations suggesting the need of a molecular genetics and functional work-up of these rare variants. We report two cases: one girl suffering from typical skin and skeletal abnormalities, developmental delay, microcephaly, thin corpus callosum, periventricular gliosis and drug-resistant epilepsy caused by a PORCN nonsense-mutation (c.283C > T, p.Arg95Ter). Presence of these combined neurological features indicates that CNS-vulnerability might be a guiding symptom in the diagnosis of GS patients. The other patient is a boy with a supernumerary nipple and skeletal anomalies but also, developmental delay, microcephaly, cerebral atrophy with delayed myelination and drug-resistant epilepsy as predominant features. Skin abnormalities were not observed. Genotyping revealed a novel PORCN missense-mutation (c.847G > C, p.Asp283His) absent in the Genome Aggregation Database (gnomAD) but also identified in his asymptomatic mother. Given that non-random X-chromosome inactivation was excluded in the mother, fibroblasts of the index had been analyzed for PORCN protein-abundance and -distribution, vulnerability against additional ER-stress burden as well as for protein secretion revealing changes. Our combined findings may suggest incomplete penetrance for the p.Asp283His variant and provide novel insights into the molecular etiology of GS by adding impaired ER-function and altered protein secretion to the list of pathophysiological processes resulting in the clinical manifestation of GS.

Sections du résumé

BACKGROUND
Goltz syndrome (GS) is a X-linked disorder defined by defects of mesodermal- and ectodermal-derived structures and caused by PORCN mutations. Features include striated skin-pigmentation, ocular and skeletal malformations and supernumerary or hypoplastic nipples. Generally, GS is associated with in utero lethality in males and most of the reported male patients show mosaicism (only three non-mosaic surviving males have been described so far). Also, precise descriptions of neurological deficits in GS are rare and less severe phenotypes might not only be caused by mosaicism but also by less pathogenic mutations suggesting the need of a molecular genetics and functional work-up of these rare variants.
RESULTS
We report two cases: one girl suffering from typical skin and skeletal abnormalities, developmental delay, microcephaly, thin corpus callosum, periventricular gliosis and drug-resistant epilepsy caused by a PORCN nonsense-mutation (c.283C > T, p.Arg95Ter). Presence of these combined neurological features indicates that CNS-vulnerability might be a guiding symptom in the diagnosis of GS patients. The other patient is a boy with a supernumerary nipple and skeletal anomalies but also, developmental delay, microcephaly, cerebral atrophy with delayed myelination and drug-resistant epilepsy as predominant features. Skin abnormalities were not observed. Genotyping revealed a novel PORCN missense-mutation (c.847G > C, p.Asp283His) absent in the Genome Aggregation Database (gnomAD) but also identified in his asymptomatic mother. Given that non-random X-chromosome inactivation was excluded in the mother, fibroblasts of the index had been analyzed for PORCN protein-abundance and -distribution, vulnerability against additional ER-stress burden as well as for protein secretion revealing changes.
CONCLUSIONS
Our combined findings may suggest incomplete penetrance for the p.Asp283His variant and provide novel insights into the molecular etiology of GS by adding impaired ER-function and altered protein secretion to the list of pathophysiological processes resulting in the clinical manifestation of GS.

Identifiants

pubmed: 35101074
doi: 10.1186/s13023-021-02068-w
pii: 10.1186/s13023-021-02068-w
pmc: PMC8802438
doi:

Substances chimiques

Membrane Proteins 0
Acyltransferases EC 2.3.-
PORCN protein, human EC 2.3.1.-

Types de publication

Case Reports Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

29

Informations de copyright

© 2022. The Author(s).

Références

Nat Rev Neurol. 2017 Aug;13(8):477-491
pubmed: 28731040
Br J Dermatol. 2009 May;160(5):1103-9
pubmed: 19292719
Cilia. 2012 May 02;1(1):7
pubmed: 23351924
J Inherit Metab Dis. 2020 Mar;43(2):297-308
pubmed: 31339582
Hum Mol Genet. 2018 Apr 15;27(8):1434-1446
pubmed: 29462312
Dev Biol. 2011 Jul 15;355(2):275-85
pubmed: 21554866
Cell Res. 2009 May;19(5):532-45
pubmed: 19365405
J Eur Acad Dermatol Venereol. 2011 May;25(5):592-5
pubmed: 20626533
Bioorg Med Chem. 2014 Sep 15;22(18):5038-9
pubmed: 25023542
Pediatr Dermatol. 2014 Mar-Apr;31(2):220-4
pubmed: 24387693
Neuromuscul Disord. 2017 Nov;27(11):1054-1064
pubmed: 28864117
Acta Ophthalmol (Copenh). 1970;48(3):525-36
pubmed: 4990274
Proc Natl Acad Sci U S A. 2011 Aug 2;108(31):12752-7
pubmed: 21768372
Indian J Dermatol. 2016 Nov-Dec;61(6):700
pubmed: 27904205
Hum Mutat. 2011 Jul;32(7):723-8
pubmed: 21472892
Mol Neurobiol. 2016 Oct;53(8):5527-41
pubmed: 26468156
J AAPOS. 2014 Apr;18(2):205-7
pubmed: 24698628
J Biol Chem. 2017 Aug 18;292(33):13507-13513
pubmed: 28655768
Dermatologica. 1961 Jan;122:50-2
pubmed: 13716117
Nucleic Acids Res. 2000 Sep 15;28(18):3442-4
pubmed: 10982861
Nat Genet. 2007 Jul;39(7):833-5
pubmed: 17546031
Handb Exp Pharmacol. 2018;245:191-225
pubmed: 29071510
Nat Rev Mol Cell Biol. 2012 Jan 18;13(2):89-102
pubmed: 22251901
Sci Rep. 2016 Feb 18;6:19418
pubmed: 26887613
Eur J Hum Genet. 2020 Mar;28(3):383-387
pubmed: 31558842
Prog Neurobiol. 2016 Jun;141:61-82
pubmed: 27095262
J Med Genet. 2009 Oct;46(10):716-20
pubmed: 19586929
Am J Dermatopathol. 1998 Apr;20(2):147-54
pubmed: 9557783
Pediatr Neurol. 2011 Feb;44(2):135-8
pubmed: 21215914
Am J Med Genet. 1988 Aug;30(4):917-23
pubmed: 3189414
Int J Dermatol. 2014 Dec;53(12):1481-4
pubmed: 25040319
Brain. 2021 Sep 4;144(8):2427-2442
pubmed: 33792664
Australas J Dermatol. 2011 Feb;52(1):48-51
pubmed: 21332693
Dev Cell. 2006 Dec;11(6):791-801
pubmed: 17141155
Am J Med Genet A. 2011 May;155A(5):1102-5
pubmed: 21484999
Am J Med Genet C Semin Med Genet. 2016 Mar;172C(1):9-20
pubmed: 26853229
Orphanet J Rare Dis. 2021 Feb 9;16(1):73
pubmed: 33563298
Nat Commun. 2017 Jul 25;8(1):126
pubmed: 28743881
J Proteomics. 2012 Feb 2;75(4):1454-62
pubmed: 22166745
PLoS One. 2019 Feb 22;14(2):e0212711
pubmed: 30794657
Pediatr Dermatol. 2011 Sep-Oct;28(5):550-4
pubmed: 21133992
Neuroscientist. 2018 Feb;24(1):54-72
pubmed: 28459188
Annu Rev Cell Dev Biol. 2004;20:781-810
pubmed: 15473860
Mt Sinai J Med. 1970 Nov-Dec;37(6):702-9
pubmed: 5312676
Hum Mutat. 2009 May;30(5):E618-28
pubmed: 19309688
Eur J Hum Genet. 2015 Apr;23(4):551-4
pubmed: 25026905
Mol Genet Metab Rep. 2017 Jun 07;12:57-61
pubmed: 28626639
Nature. 2005 Apr 14;434(7035):843-50
pubmed: 15829953
An Esp Pediatr. 1982 Jun;16(6):524-6
pubmed: 7125405
Proc Natl Acad Sci U S A. 2014 Jun 10;111(23):8488-93
pubmed: 24889604
Cell Rep. 2016 Feb 2;14(4):782-794
pubmed: 26776514
Nat Genet. 2007 Jul;39(7):836-8
pubmed: 17546030
Pediatr Dermatol. 2012 May-Jun;29(3):324-6
pubmed: 21995324
Arch Dermatol. 1962 Dec;86:708-17
pubmed: 13948891
Nat Genet. 2007 Jul;39(7):820-1
pubmed: 17597772

Auteurs

Annabelle Arlt (A)

Institute of Clinical Genetics and Tumor Genetics, Bonn, Germany.

Nicolai Kohlschmidt (N)

Institute of Clinical Genetics and Tumor Genetics, Bonn, Germany.

Andreas Hentschel (A)

Leibniz Institute for Analytical Sciences (ISAS), Dortmund, Germany.

Enrika Bartels (E)

Institute of Clinical Genetics and Tumor Genetics, Bonn, Germany.

Claudia Groß (C)

Institute of Clinical Genetics and Tumor Genetics, Bonn, Germany.

Ana Töpf (A)

John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK.

Pınar Edem (P)

Department of Medical Biology, School of Medicine, Dokuz Eylul University, Izmir, Turkey.

Nora Szabo (N)

Department of Clinical Neurosciences, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK.

Albert Sickmann (A)

Leibniz Institute for Analytical Sciences (ISAS), Dortmund, Germany.

Nancy Meyer (N)

Pediatric Neurology, Faculty of Medicine, University of Duisburg-Essen, University Hospital, Essen, Germany.

Ulrike Schara-Schmidt (U)

Pediatric Neurology, Faculty of Medicine, University of Duisburg-Essen, University Hospital, Essen, Germany.

Jarred Lau (J)

Children's Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, ON, Canada.

Hanns Lochmüller (H)

Children's Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, ON, Canada.
Division of Neurology, Department of Medicine, The Ottawa Hospital, Ottawa, ON, Canada.
Brain and Mind Research Institute, University of Ottawa, Ottawa, Canada.
Centro Nacional de Análisis Genómico (CNAG-CRG), Center for Genomic Regulation, Barcelona Institute of Science and Technology (BIST), Barcelona, Catalonia, Spain.

Rita Horvath (R)

Department of Clinical Neurosciences, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK.

Yavuz Oktay (Y)

Department of Medical Biology, School of Medicine, Dokuz Eylul University, Izmir, Turkey.
Izmir Biomedicine and Genome Center, Dokuz Eylul University Health Campus, Izmir, Turkey.
Izmir International Biomedicine and Genome Institute, Dokuz Eylul University, Izmir, Turkey.

Andreas Roos (A)

Department of Clinical Neurosciences, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK. roos@andreas-roos.de.
Children's Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, ON, Canada. roos@andreas-roos.de.

Semra Hiz (S)

Izmir Biomedicine and Genome Center, Dokuz Eylul University Health Campus, Izmir, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH